Slide 1: Quarter 2026 Results
34 Quarter 2026 Results Johnson & Johnson's strong third-quarter performance and Worldwide Innovative Medicine sales Worldwide MedTech sales increased sequential growth Innovative Medicine worldwide reported sales MedTech worldwide sales increased 2.5% reflect the accelerating increased 7.7% or 7.9%
Slide 2: 3rd Quarter 2026 Earnings Call
3 Quarter 2026 rd Earnings Call October 13, 2026
Slide 3: Cautionary note on Forward-looking statements
Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business st
Slide 4: Strategic partnerships, collaborations & licensing arrangements
Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships:
Slide 5: Agenda
Agenda 1 CEO Remarks 2 Sales performance and earnings review 3 Capital allocation and guidance update 4 Q&A Joaquin Duato Tom Cavanaugh Tim Schmid Chairman and Executive Vice President, Executive Vice President, Chief Executive Officer Worldwide Chairman, Worldwide Chairman, Innovative Medicine MedT
Slide 6: Joaquin Duato
Joaquin Duato Chairman and Chief Executive Officer
Slide 7: Q3 Earnings Summary
Q3 Earnings Summary Six key businesses driving growth 6.0% Oncology Immunology Neuroscience operational sales Cardiovascular Surgery Vision growth 1,2 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's we
Slide 8: 29 Platforms / Products > 1 Billion in Annual Sales
29 Platforms / Products > 1 Billion in Annual Sales Innovative Medicine (16) MedTech (13) Electrophysiology Contact Wound Trauma Lenses Closure Biosurgery Abiomed Hips Knees Surgical Endocutters Vision Energy Shockwave Spine 8
Slide 9: Innovative Medicine: 7.9% operational sales growth
Innovative Medicine: 7.9% operational sales growth 1,2 Oncology Immunology Neuroscience 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (690) basis point headwind from
Slide 10: MedTech: 2.5% operational sales growth
MedTech: 2.5% operational sales growth 1 Cardiovascular Surgery Vision ACUVUE® OASYS 1-Day Family VARIPULSE Platform Dual Energy THERMOCOOL ETHICON 4000 Surgical Stapler OTTAVA Robotic SMARTTOUCH SF Catheter with 3D Stapling Technology Surgical System Shockwave Intravascular Impella® Heart OMNYPULSE
Slide 11: OTTAVA U.S. FDA market authorization opens a new category in surgical robotics
OTTAVA U.S. FDA market authorization opens a new category in surgical robotics The world’s first table-integrated soft tissue robotic system — four arms built into a standard surgical table Surgery De Novo authorization spans 10 general surgery procedures, including: • Gastric bypass • Cholecystecto
Slide 12: MedTech: 2.5% operational sales growth
MedTech: 2.5% operational sales growth 1 Cardiovascular Surgery Vision ACUVUE® OASYS 1-Day Family VARIPULSE Platform Dual Energy THERMOCOOL ETHICON 4000 Surgical Stapler OTTAVA Robotic SMARTTOUCH SF Catheter with 3D Stapling Technology Surgical System Shockwave Intravascular Impella® Heart OMNYPULSE
Slide 13: Johnson & Johnson is built for durable growth
Johnson & Johnson is built for durable growth 13
Slide 14: Ryan Koors
Ryan Koors Vice President, Investor Relations
Slide 15: 3rd Quarter 2026 sales
3rd Quarter 2026 sales % Change Dollars in billions Regional sales results Q3 2026 Q3 2025 Reported Operational1 U.S. $15.0 $13.7 9.1% 9.1% Europe 5.4 5.4 (0.6) 1.0 Western Hemisphere 1.4 1.2 12.5 8.0 (ex U.S.) Asia-Pacific, Africa 3.7 3.6 1.0 1.0 International 10.4 10.3 1.5 1.8 Worldwide (WW) $25.4
Slide 16: 3rd Quarter 2026 financial highlights
3rd Quarter 2026 financial highlights Dollars in billions, except EPS Reported %; Operational %1 Sales GAAP earnings GAAP EPS $25.4 $24.0 $2.12 $5.2 Includes one- Includes one- time special time special charges charges $0.23 $0.093 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 5.9%; 6.0%1 (95.9)%
Slide 17: Innovative Medicine highlights – 3rd quarter 2026
Innovative Medicine highlights – 3rd quarter 2026 Strong operational growth1 of 7.9% driven primarily by new product launches Stelara impacted results1 by ~(690) basis points Key drivers of operational performance1 • DARZALEX increase primarily driven by strong share gains and market growth Reported
Slide 18: MedTech highlights – 3rd quarter 2026
MedTech highlights – 3rd quarter 2026 Modest operational growth1 of 2.5% driven primarily by commercial execution and innovation Key drivers of operational performance1 Reported: WW 2.5%, U.S. 4.8%, Int’l 0.1% • Electrophysiology: Increase driven by procedure growth, commercial execution, and new pr
Slide 19: Condensed consolidated statement of earnings
Condensed consolidated statement of earnings 3rd Quarter 2026 2026 2025 % Increase (Unaudited; Dollars and shares in millions except per share figures) Amount % to Sales Amount % to Sales (Decrease) Sales to customers $25,399 100.0 $23,993 100.0 5.9 Cost of products sold 8,097 31.9 7,303 30.4 10.9 G
Slide 20: Adjusted earnings before provision for taxes on income by segment
Adjusted earnings before provision for taxes on income by segment 3rd Quarter 2026 (Unaudited; Dollars in millions) Innovative Medicine 2026 2025 % Increase (2026 includes the impact of M&A transactions: Firefly Bio, Inc. & Sail Biomedicines) Amount % to Sales Amount % to Sales (Decrease) Sales to c
Slide 21: Joseph J. Wolk
Joseph J. Wolk Executive Vice President, Chief Financial Officer
Slide 22: Capital allocation strategy
Capital allocation strategy Dollars in billions Q3 2026 Cash and marketable $17 securities Capital allocation Higher Debt ($45) priority Organic growth business needs Net debt ($28) Free cash flow1,2 ~$15 Free cash flow1 Note: Values may be rounded Q3 2026: $4.7B invested in R&D Competitive dividend
Slide 23: 2026 P&L guidance
2026 P&L guidance Operational2 sales guidance of 6.9% and adjusted operational EPS2,4 at 2.0% (midpoints) October 2026 July 29, 2026 Comments Tightening range; Adjusted operational sales1,2 6.4% - 6.8% 6.2% - 6.8% Increasing midpoint to 6.6% $100.5B - $100.9B $100.3B - $100.9B Tightening range; Oper
Slide 24: 2026 milestones driving long-term value creation
2026 milestones driving long-term value creation 1 Innovative Medicine MedTech TECVAYLI + TALVEY in RRMM Dual Energy THERMOCOOL STSF Pasritamig in prostate cancer C2 Aero Catheters JNJ-6143 in prostate cancer VARIPULSE Pro INLEXZO in HR NMIBC OTTAVA ICOTYDE in PsA ETHICON 4000 CAPLYTA in bipolar man
Slide 25: Q&A
Q&A Joaquin Duato Tom Cavanaugh Tim Schmid Chairman and Executive Vice President, Executive Vice President, Chief Executive Officer Worldwide Chairman, Worldwide Chairman, Innovative Medicine MedTech Joseph J. Wolk John Reed Ryan Koors Executive Vice President, Executive Vice President, Vice Preside
Slide 26: Slide footer goes here if required
Slide footer goes here if required 26
Slide 27: Johnson & Johnson Innovative Medicine Pipeline Key Events in 2026
Johnson & Johnson Innovative Medicine Pipeline Key Events in 2026* POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹ Phase III Phase I/ II US TREMFYA (guselkumab) US IMAAVY (nipocalimab) US ERLEADA (apalutamide) ICOTYDE (icotrokinra) ERLEADA (apalutamid